Overview

Detailed Summary

Vimta Labs Limited is a comprehensive contract research and testing organization serving industries like pharmaceuticals, food, electronics, and environment testing. With expertise in drug discovery and development, it offers pivotal support for numerous sectors.
The company has experienced a commendable 10.2% year-on-year revenue growth as of Q3 FY26, showcasing resilience and effective market penetration. The diverse testing services offered have significantly contributed to these earnings.
Strategic capacity expansion, especially in biologics and electronics sectors, hints at Vimta Labs Limited's commitment to seize emerging opportunities, reflecting a calculated approach to maximize its operational footprint.
International business continues to bolster Vimta Labs Limited's financial trajectory, with exports contributing around 39% of their income, underscoring its strong global presence, particularly in pharmaceutical analytical services.

Sector: Healthcare
Industry: Diagnostic Services
Market Cap: 1,918 Cr
Volatility: Low Risk
P/E Ratio: 31.6
Industry P/E: 42.1
PEG Ratio: 1.4
P/B Ratio: 5.6
52W High: 902.85
52W Low: 372.50

Sales CAGR

1Y: 0.02%
3Y: 7.62%
5Y: 13.74%
10Y: 11.93%

Profit CAGR

1Y: -14.86%
3Y: 17.59%
5Y: 57.32%
10Y: 29.69%

ROE

TTM: 14.59%
3Y: 15.99%
5Y: 15.55%
10Y: 13.13%

ROCE

TTM: 19.04%
3Y: 21.22%
5Y: 20.28%
10Y: 17.52%

Technicals

‌

Forecasts

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
KRSNAA	609.60	1,951 Cr	24.97	2.11	0.46	9.16	11.09	5.34
VIMTALABS	428.00	1,918 Cr	31.55	5.60	0.23	14.59	19.04	13.94
SURAKSHA	270.00	1,384 Cr	42.25	6.01	0.00	13.86	14.74	8.53
ONEGLOBAL	595.05	1,163 Cr	23.72	11.48	0.00	43.51	58.07	27.58
CHANDAN	258.80	633 Cr	24.01	4.58	0.00	18.69	20.84	10.52
QLL	319.00	372 Cr	45.06	2.68	0.00	0.00	0.00	2.06
MDRCL	75.40	114 Cr	9.25	1.98	0.00	43.27	33.60	13.89

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	80	77	82	83	66	82	80	75	85	90
Expenses	54	56	58	59	48	60	55	49	55	57
Operating Profit	25	21	24	25	17	22	24	26	30	33
OPM %	31.77	27.72	29.54	29.54	26.56	26.74	30.64	34.63	35.28	36.79
Other Income	0.76	1.12	0.67	0.59	2.04	0.90	0.49	0.69	0.68	1.23
Interest	0.80	0.65	0.25	0.44	0.61	0.54	0.53	0.47	0.41	0.58
Depreciation	7.58	7.85	8.04	8.50	8.65	8.69	8.09	7.98	8.29	9.81
Profit Before Tax	18	14	17	16	10	14	16	18	22	24
Tax %	25.62	27.27	23.38	25.21	20.41	24.94	24.14	23.45	22.29	26.76
Net Profit	13	10	13	12	8.11	10	12	14	17	18
EPS in Rs	2.90	2.24	2.80	2.68	1.40	2.23	2.74	2.72	3.35	4.76

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	181	211	278	318	318	329
Expenses	151	158	198	223	231	216
Operating Profit	30	53	80	95	87	113
OPM %	16.57	25.14	28.85	29.83	27.27	34.42
Other Income	3.02	0.83	0.23	3.44	4.01	3.09
Interest	3.77	2.17	1.50	2.65	2.12	1.99
Depreciation	21	23	23	31	34	34
Profit Before Tax	8.27	29	56	65	54	80
Tax %	17.23	25.00	25.78	25.89	24.73	24.25
Net Profit	6.85	21	41	48	41	61
EPS in Rs	—	3.11	9.12	10.57	9.05	13.56
Dividend Payout %	0.00	20.66	10.92	9.37	10.96	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity Capital	4.42	4.42	4.42	4.43	4.43
Reserves	168	190	230	277	315
Borrowings	23	30	19	15	19
Other Liabilities	50	50	54	66	61
Total Liabilities	246	274	307	362	400
Fixed Assets	138	135	169	175	171
CWIP	1.82	17	0.31	12	59
Investments	0.00	0.00	0.00	0.00	0.00
Other Assets	106	122	138	175	170
Total Assets	246	274	307	362	400

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity	24	37	59	88	61
Cash from Investing Activity	-21	-32	-38	-57	-76
Cash from Financing Activity	-0.67	-4.57	-17	-11	-1.90
Net Cash Flow	2.84	0.69	4.61	20	-17

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	37.24%	37.23%	37.01%	36.98%	36.92%	36.89%	36.89%	36.76%	36.70%	36.66%	35.99%	35.90%
FIIs	2.25%	2.72%	2.74%	2.88%	5.13%	5.16%	3.31%	3.81%	3.66%	3.52%	4.33%	4.59%
DIIs	2.14%	2.13%	1.50%	1.49%	1.50%	1.49%	0.00%	1.16%	1.43%	1.42%	0.87%	0.11%
Public	58.38%	57.92%	58.75%	58.66%	56.45%	56.46%	59.80%	58.27%	58.20%	58.40%	58.80%	59.41%
Total Shareholders	17,162	17,439	18,429	19,957	18,550	19,054	20,114	21,156	26,183	29,876	55,933	54,467

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Available on Pro Plan